21 May 2013
Keywords: Antisoma, Novartis, Lung cancer, ASA404, Research
Article | 29 March 2010
UK cancer drug developer Antisoma revealed this morning that the planned interim analysis of data from the ATTRACT-1 Phase III ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 March 2010
30 March 2010
20 May 2013
© 2013 thepharmaletter.com